Dianthus Therapeutics announced Q1 2026 financial results and key business updates, including an early go decision in their Phase 3 CAPTIVATE trial for claseprubart in CIDP after achieving 20 responders early. The company is on track to start a Phase 3 trial for generalized Myasthenia Gravis mid-2026 and expects top-line results by late 2028. They also continue Phase 2 trials for Multifocal Motor Neuropathy and Phase 1 trials for DNTH212 targeting rheumatology diseases. Dianthus strengthened its cash position to approximately $1.2 billion after raising $719 million in a public offering, providing runway into 2030. These developments position Dianthus to advance its pipeline of next-generation autoimmune therapies.
Roku President Charles Collier sold 20,538 shares of the company, raising $3 million from the transaction. This insider sale could indicate personal financial planning or a shift in confidence, but no further details were provided. Investors may watc...
Bitcoin's blockchain split at block 961632, with the BIP-110-supporting Roughnecks mining two blocks on a minority chain now 18 blocks behind the main chain, which has reached block 961651. The mining difficulty remains high at 127.48 trillion, makin...
Tron's stablecoin supply reached approximately $91.8 billion in early August, increasing by $2 billion in the past month. Nearly 98% of this supply is Tether's USDT, making Tron the largest blockchain for USDT circulation since 2021. The network proc...
Roku President Charles Collier sold 20,538 shares of the company, generating $3 million in proceeds. This insider sale could indicate personal financial planning or a shift in confidence, which investors might watch closely. The transaction highlight...
SharpLink CEO Joseph Chalom warned that Ethereum's proposed EIP-8363, which would burn a portion of validator rewards as staking increases, might harm DeFi liquidity, raise borrowing costs, and discourage institutional ETH ownership. The proposal aim...
